Yungjin Pharm. Co., Ltd. (003520.KS) Stock

003520.KS logo

Yungjin Pharm. Co., Ltd.

003520.KSSouth Korea
Healthcare

Company profile

Yungjin Pharm. reported revenue of 254.26 billion KRW for fiscal year 2025, up 0.9% from fiscal year 2024. In Q1 2026 (the quarter ended March 31, 2026) revenue was 63.76 billion KRW, down 0.5% from a year before. In Q1 2026 it reported a net loss of 2.28 billion KRW, against net income of 976.29 million KRW a year earlier. Our analysis of its filings shows revenue growing from 234.90 billion KRW in fiscal year 2023 to 254.26 billion KRW in fiscal year 2025, 4.0% a year on average.

What stands out

  • It reported a net loss of 227.66 million KRW in fiscal year 2025, after a profit of 1.23 billion KRW in fiscal year 2024.
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Yungjin Pharm. Co., Ltd.

Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. operates as a subsidiary of KT&G Corporation.

Largest shareholders

  • Kt&G Corporation52.45%

Share of the company, as of September 25, 2026

Leadership

  • Kisoo Lee — Chairman of the Board of Directors, President & CEO, 59
  • ByeongHo Park — CFO & MD, 58
  • UngYeol Yang — MD & GM of Sales HQ, 48
  • Joongyoun Cho — MD & Global Headquarters GM, 46
  • HongJun Park — Managing Director, 51

How much revenue does Yungjin Pharm. make?

Yungjin Pharm. reported 254.26 billion KRW in revenue for fiscal year 2025, up 0.9% from 252.04 billion KRW in fiscal year 2024. In Q1 2026 revenue was 63.76 billion KRW.

What companies are similar to Yungjin Pharm.?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ilsung Is Co., Ltd. (003120.KS), Samil Pharmaceutical Co.,Ltd (000520.KS), Hana Pharm Co., Ltd. (293480.KS), Dongwha Pharm.Co.,Ltd (000020.KS).

Has Yungjin Pharm. made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 11.58 billion KRW; FY2022, a loss of 21.96 billion KRW; FY2023, a loss of 3.88 billion KRW; FY2024, 1.23 billion KRW; FY2025, a loss of 227.66 million KRW. It reported a net loss in 4 of these 5 years.

How has Yungjin Pharm.'s revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 196.07 billion KRW; FY2022, 218.38 billion KRW; FY2023, 234.90 billion KRW; FY2024, 252.04 billion KRW; FY2025, 254.26 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
Jamsil Company Building, Seoul, 05510
Phone
82 2 2041 8200
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Yungjin Pharm. Co., Ltd. (003520.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/003520.KS

LinkedInLinkedInXXYouTubeYouTube